DEADLINE FOR POSTER SUBMISSION IS PROLONGED UNTIL MAY 26, 24.00h
The European Foundation for Clinical Nanomedicine (CLINAM) and the European Technology Platform on Nanomedicine (ETPN) organize the annual gathering on Clinical Nanomedicine and Targeted Medicine that has become an international landmark.
This years’ focus topic is: “Nanomedicine & Targeted Medicine – the paradigm of precise, highly effective and safe medicine with subtle influence for the benefit of patients and mankind”. - We aim presenting lessons learned, facts and figures regarding progress in development and characterization of nanomedicines.
Nanomedicines are now available and translated from Research to Targeted Medicines. Many of them are on the way to provide concrete benefit for patients. As the awareness of clinicians has largely increased and a significant number of proof-of-concepts, non-clinical and clinical studies are under development, this is attracting the venture capital community, large pharmaceutical companies, health-technology companies and SME’s to invest in the field.
The interdisciplinary faculty of all stakeholders intends to share novel ideas in Basel for making innovative drugs and devices available. This is the unique forum for creative scientists to propose new ideas and for established research organizations, industries and funding organizations to provide opportunities for further growth of this area.
The communities of Academia, Government, Health Economy and Industry are Called to Participate
The Sessions will identify the challenges and indicate solution strategies for Nanomedicines and Targeted Medicines to provide new tools supporting the health care systems with cost effective approaches. The 2013 summit strives to bring together the most skilled people in an effort to shape this scientific field and thereby push the boundaries of cutting-edge Nanomedicine.
Venue: June 23-26, 2013 - Congress Center Basel, Messeplatz 21, Basel, Switzerland
Scientific Committee of the Conference of CLINAM 6/13
• Prof. Dr. med. Patrick Hunziker, University Hospital Basel (CH) (Chairman) • Prof. Dr. Yechezkel Barenholz, Hebrew University, Hadassah Medical School, Jerusalem (IL) • Beat Löffler, MA, European Foundation for Clinical Nanomedicine (CLINAM), Basel (CH) • Prof. Dr. Gert Storm, Institute for Pharmaceutical Sciences, Utrecht University, Utrecht (NL) • Prof. Dr. Marisa Papaluca Amati, European Medicines Agency, London (UK) • Prof. Dr. med. Janos Szebeni, Nanomedicine Research and Education Center, Semmelweis University/Dept. Nanobiotechnology, Miskolc University and SeroScience Inc., Budapest (H) • Prof. Dr. med. Christoph Alexiou, Head and Neck Surgery, University Hospital Erlangen (D) • Prof. Dr. Claus-Michael Lehr, Helmholtz-Institute for Pharm. Research Saarland (HIPS), Saarbrucken (D) • Patrick Boisseau, CEA-Léti, Chairman of the Board of the ETPN. Grenoble (F) • Prof. Dr. Viola Vogel, Laboratory for Biologically Oriented Materials, ETH, Zürich (CH) • Prof. Dr. Jan Mollenhauer, University of Southern Denmark and NanoCAN, Odense (DK) • Dr. Yanay Ofran, Systems Biology & Functional Genomics, Bar Ilan University, Ramat Gan (IL)
Joint Collaborating Parties
European Foundation for Clinical Nanomedicine (CLINAM), Basel (CH) • European Technology Platform on Nanomedicine (ETPN), Berlin (D) • The International Association for Pharmaceutical Technology, Focus Group "Drug Delivery" (APV), Mainz (D) • European Society for Nanomedicine (ESNAM), Basel (CH) • Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Saarbrücken (D) • BioNanoNet Research Association" (BioNanoNet), Graz (A) • EU, Directorate-General for Research & Innovation (RTD), Brussels (B) • European Association for Predictive and Preventive and Personalized Medicine (EPMA) Brussels (B) • European Platform for Photodynamic Medicine (EPPM), Hull (UK) • European Materials Research Society (E-MRS), Strasbourg (F)
Target Audience
The faculty includes the pioneers and opinion leaders in the fields of medicine, nanoscience and targeted medicine, who share their experience in an interdisciplinary and interactive manner that widens mutual understanding for both sides. The conference and the exhibition are aimed at physicians, as well as nanoscientists with a background in pharmacology, biology, physics, chemistry, biophysics, medicine materials science and engineering and for decision makers from Universities and Research Institutes. The meeting is of high knowledge profit for the community of targeted medicine and targeted delivery. The conference is also of interest for policymakers, experts from industry in the field of life sciences, developers of new tools and materials for nanomedicine, all those investigating in the future potential of emerging technologies. Experts from venture companies can acquire knowledge on existing and upcoming developments and novel products in the emerging field of Nanomedicine; government authorities related to health profit of the regulator’s sessions.
The Foundation
The European Foundation for Clinical Nanomedicine is a non-profit institution aiming at advancing medicine to the benefit of individuals and society through the application of nanoscience. Aiming at prevention, diagnosis, and therapy through nanomedicine as well as at exploration of its implications, the Foundation reaches its goals through support of clinically focussed research and of interaction and information flow between clinicians, researchers, the public, and other stakeholders. The recognition of the large future impact of nanoscience on medicine and the observed rapid advance of medical applications of nanoscience have been the main reasons for the creation of the Foundation.
Nanotechnology for Medicine
Nanotechnology is generally considered as the key technology of the 21st century. It is an interdisciplinary scientific field focusing on methods, materials, and tools on the nanometer scale, i.e. one millionth of a millimeter. The application of this science to medicine seeks to benefit patients by providing prevention, early diagnosis, and effective treatment for prevalent, for disabling, and for currently incurable medical conditions.
